While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

Research on organic solar cells has been conducted for a long time. Recent advancements in understanding their molecular ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...

When active filaments are exposed to localized illumination, they accumulate into stable structures along the boundaries of ...

Empaveli could achieve peak sales of $700 million by 2031, targeting C3G and IC-MPGN markets. Syfovre is expected to reach U.S. peak sales of $2 billion by 2030, driven by strong demand and ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of ...

Google DeepMind releases AlphaFold 3's source code to academics, marking a significant advance in AI-powered molecular biology and drug discovery, while balancing open science with commercial ...

The analyst has initiated the coverage with an Outperform rating and estimates a fair value for shares of $50. Syfovre received approval in February 2023, while Astellas Pharma Inc’s (OTC:ALPMF) ...

Over the past few months, we have made meaningful progress towards our long-term goals, reaching key milestones such as generating continued growth in vial demand for SYFOVRE and presenting the ...